Insider Selling: Amphastar Pharmaceuticals (NASDAQ:AMPH) EVP Sells $239,400.00 in Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) EVP Rong Zhou sold 10,000 shares of the stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $23.94, for a total value of $239,400.00. Following the completion of the transaction, the executive vice president owned 169,203 shares in the company, valued at approximately $4,050,719.82. The trade was a 5.58% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Rong Zhou also recently made the following trade(s):

• On Wednesday, September 2nd, Rong Zhou sold 3,187 shares of Amphastar Pharmaceuticals stock. The stock was sold at an average price of $23.63, for a total value of $75,308.81.

Amphastar Pharmaceuticals Stock Down 0.5%

AMPH traded down $0.13 on Thursday, reaching $23.82. The company’s stock had a trading volume of 465,639 shares, compared to its average volume of 514,906. The stock has a 50 day moving average of $21.10 and a two-hundred day moving average of $20.30. The company has a quick ratio of 1.71, a current ratio of 2.40 and a debt-to-equity ratio of 0.79. The company has a market capitalization of $1.01 billion, a price-to-earnings ratio of 14.09, a P/E/G ratio of 4.55 and a beta of 0.92. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $16.65 and a fifty-two week high of $29.52.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.91 earnings per share for the quarter, topping analysts’ consensus estimates of $0.62 by $0.29. The company had revenue of $183.90 million for the quarter, compared to analysts’ expectations of $179.92 million. Amphastar Pharmaceuticals had a net margin of 10.76% and a return on equity of 14.98%. As a group, analysts forecast that Amphastar Pharmaceuticals, Inc. will post 2.46 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on AMPH. Wells Fargo & Company upped their price objective on shares of Amphastar Pharmaceuticals from $19.00 to $20.00 and gave the company an “equal weight” rating in a research note on Friday, August 7th. Bank of America reiterated an “underperform” rating and set a $20.00 target price (down from $25.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, June 29th. Zacks Research raised Amphastar Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 21st. Piper Sandler decreased their target price on Amphastar Pharmaceuticals from $21.00 to $20.00 and set a “neutral” rating for the company in a research report on Friday, August 7th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Amphastar Pharmaceuticals in a research note on Wednesday, July 8th. Six investment analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Reduce” and an average target price of $22.50.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of AMPH. Quantbot Technologies LP acquired a new position in Amphastar Pharmaceuticals during the second quarter worth about $39,000. TD Private Client Wealth LLC increased its stake in shares of Amphastar Pharmaceuticals by 410.1% during the 4th quarter. TD Private Client Wealth LLC now owns 2,418 shares of the company’s stock worth $65,000 after purchasing an additional 1,944 shares in the last quarter. Hantz Financial Services Inc. raised its position in shares of Amphastar Pharmaceuticals by 43.6% during the 4th quarter. Hantz Financial Services Inc. now owns 4,484 shares of the company’s stock worth $120,000 after purchasing an additional 1,362 shares during the last quarter. State of Wyoming acquired a new position in shares of Amphastar Pharmaceuticals in the second quarter worth $142,000. Finally, ProShare Advisors LLC raised its stake in Amphastar Pharmaceuticals by 5.3% in the 4th quarter. ProShare Advisors LLC now owns 9,083 shares of the company’s stock valued at $243,000 after purchasing an additional 457 shares during the last quarter. Institutional investors and hedge funds own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a biopharmaceutical company that develops, manufactures and markets injectable, inhaled and intranasal products. The company focuses on complex and technically challenging medicines, including products for diabetes, emergency medicine, respiratory conditions and other specialty-care applications.

Its marketed products include glucagon for treating severe hypoglycemia, BAQSIMI nasal glucagon, Primatene MIST for temporary relief of mild intermittent asthma symptoms, naloxone products for opioid overdose emergencies, and enoxaparin sodium injection, an anticoagulant.